Carvykti(ciltacabtagene autoleucel, cilta-cel )西达基奥仑赛,又名为JNJ-4528/LCAR-B38M,是一种具有差异性结构的嵌合抗原受体T细胞(CAR-T)细胞疗法,包含一个4-1BB共刺激结构域,及两个靶向B细胞成熟抗原(BCMA)的抗体结构域。BCMA是一种在骨髓瘤细胞上高度表达的蛋白,是治疗多发性骨髓瘤的理想靶点。 1....
CAR- PRISM (PRecision Intervention Smoldering Myeloma): A Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in High-Risk Smoldering Myeloma The goal of this research study is to test if ciltacabtagene autoleucel (cilta-cel) is safe and effective in treating participants ...
However, the comprehensive chronological pathophysiologic landscape of CRS upon CAR-T therapy hasn’t yet been fully elucidated. Ciltacabtagene autoleucel (Cilta-cel, previously known as LCAR-B38M) is a biepitopic CAR-T product targeting BCMA antigen, and has achieved remarkable success in the...